Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine

J. Southern; A. Crowley-Luke; R. Borrow; N. Andrews; E. Miller

doi:10.1016/j.vaccine.2005.07.060

Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine

J. Southern^*, A. Crowley-Luke, R. Borrow, N. Andrews, E. Miller

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

Abstract

Reduction of the number of injections necessary to confer protection in the infant schedule would reduce discomfort, improve cost-effectiveness and create space for the addition of new vaccinations in the future. This study assessed the immunogenicity of one, two or three doses of meningococcal C conjugate vaccine conjugated to tetanus toxoid (MCC-TT) [Neis-VacC^®] given concomitantly with a combined diphtheria/tetanus/acellular pertussis/Haemophilus influenzae type b -TT conjugate (DTaP-Hib-TT) [Infanrix-Hib^®] vaccine at 2, 3 and 4 months of age. A total of 106 healthy UK infants were enrolled and randomised into two groups, one in which blood was taken after the first and third dose and the other after the second and third dose. The meningococcal serogroup C serum bactericidal antibody (SBA) geometric mean titre (GMT) rose significantly from post-first dose (491, 95% CI 275, 877) to post-second dose (1052, 95% CI 774, 1433) (p = 0.03), with no significant change after the third dose (1024, 95% CI 768, 1366). An SBA titre of ≥8 was achieved by 92% after the first dose and 100% after the second and third doses. The Hib IgG geometric mean concentration (GMC) rose significantly after each dose: post-first (0.14 μg/ml 95% CI 0.10, 0.18), post-second (0.54 μg/ml, 95% CI 0.33, 0.90), post-third (2.04 μg/ml, 95% CI 1.52, 2.74). The Hib GMC after the third dose was higher than reported previously when this DTaP/Hib was given either on its own or concomitantly with a MCC-CRM conjugate vaccine according to the UK 2, 3 and 4 month schedule. This suggests some enhancement of the response to a Hib-TT vaccine by concomitant administration of MCC-TT. These results suggest that a reduced number of doses of MCC-TT would be adequate in infancy if given concomitantly with an acellular pertussis-containing vaccine.

Original language	English
Pages (from-to)	215-219
Number of pages	5
Journal	Vaccine
Volume	24
Issue number	2
DOIs	https://doi.org/10.1016/j.vaccine.2005.07.060
Publication status	Published - 12 Jan 2006

Bibliographical note

Funding Information:
We wish to thank the Vaccine Research Nurse team in Hertfordshire, the laboratory teams at Porton and Manchester and the administrative team at the Centre for Infection for their assistance in the conduct of the study. We wish to thank the Department of Health Research and Development Directorate for the provision of financial support of the study under grant number 1217470.

Keywords

Infant
Meningococcal
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2005.07.060

Fingerprint

Dive into the research topics of 'Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine'. Together they form a unique fingerprint.

Cite this

Southern, J., Crowley-Luke, A., Borrow, R., Andrews, N., & Miller, E. (2006). Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine, 24(2), 215-219. https://doi.org/10.1016/j.vaccine.2005.07.060

@article{ce4d37aa265c44b3b762cab4359ee6bc,

title = "Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine",

abstract = "Reduction of the number of injections necessary to confer protection in the infant schedule would reduce discomfort, improve cost-effectiveness and create space for the addition of new vaccinations in the future. This study assessed the immunogenicity of one, two or three doses of meningococcal C conjugate vaccine conjugated to tetanus toxoid (MCC-TT) [Neis-VacC{\textregistered}] given concomitantly with a combined diphtheria/tetanus/acellular pertussis/Haemophilus influenzae type b -TT conjugate (DTaP-Hib-TT) [Infanrix-Hib{\textregistered}] vaccine at 2, 3 and 4 months of age. A total of 106 healthy UK infants were enrolled and randomised into two groups, one in which blood was taken after the first and third dose and the other after the second and third dose. The meningococcal serogroup C serum bactericidal antibody (SBA) geometric mean titre (GMT) rose significantly from post-first dose (491, 95% CI 275, 877) to post-second dose (1052, 95% CI 774, 1433) (p = 0.03), with no significant change after the third dose (1024, 95% CI 768, 1366). An SBA titre of ≥8 was achieved by 92% after the first dose and 100% after the second and third doses. The Hib IgG geometric mean concentration (GMC) rose significantly after each dose: post-first (0.14 μg/ml 95% CI 0.10, 0.18), post-second (0.54 μg/ml, 95% CI 0.33, 0.90), post-third (2.04 μg/ml, 95% CI 1.52, 2.74). The Hib GMC after the third dose was higher than reported previously when this DTaP/Hib was given either on its own or concomitantly with a MCC-CRM conjugate vaccine according to the UK 2, 3 and 4 month schedule. This suggests some enhancement of the response to a Hib-TT vaccine by concomitant administration of MCC-TT. These results suggest that a reduced number of doses of MCC-TT would be adequate in infancy if given concomitantly with an acellular pertussis-containing vaccine.",

keywords = "Infant, Meningococcal, Vaccine",

author = "J. Southern and A. Crowley-Luke and R. Borrow and N. Andrews and E. Miller",

note = "Funding Information: We wish to thank the Vaccine Research Nurse team in Hertfordshire, the laboratory teams at Porton and Manchester and the administrative team at the Centre for Infection for their assistance in the conduct of the study. We wish to thank the Department of Health Research and Development Directorate for the provision of financial support of the study under grant number 1217470.",

year = "2006",

month = jan,

day = "12",

doi = "10.1016/j.vaccine.2005.07.060",

language = "English",

volume = "24",

pages = "215--219",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "2",

}

Southern, J, Crowley-Luke, A, Borrow, R , Andrews, N & Miller, E 2006, 'Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine', Vaccine, vol. 24, no. 2, pp. 215-219. https://doi.org/10.1016/j.vaccine.2005.07.060

Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. / Southern, J.; Crowley-Luke, A.; Borrow, R. et al.
In: Vaccine, Vol. 24, No. 2, 12.01.2006, p. 215-219.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine

AU - Southern, J.

AU - Crowley-Luke, A.

AU - Borrow, R.

AU - Andrews, N.

AU - Miller, E.

N1 - Funding Information: We wish to thank the Vaccine Research Nurse team in Hertfordshire, the laboratory teams at Porton and Manchester and the administrative team at the Centre for Infection for their assistance in the conduct of the study. We wish to thank the Department of Health Research and Development Directorate for the provision of financial support of the study under grant number 1217470.

PY - 2006/1/12

Y1 - 2006/1/12

N2 - Reduction of the number of injections necessary to confer protection in the infant schedule would reduce discomfort, improve cost-effectiveness and create space for the addition of new vaccinations in the future. This study assessed the immunogenicity of one, two or three doses of meningococcal C conjugate vaccine conjugated to tetanus toxoid (MCC-TT) [Neis-VacC®] given concomitantly with a combined diphtheria/tetanus/acellular pertussis/Haemophilus influenzae type b -TT conjugate (DTaP-Hib-TT) [Infanrix-Hib®] vaccine at 2, 3 and 4 months of age. A total of 106 healthy UK infants were enrolled and randomised into two groups, one in which blood was taken after the first and third dose and the other after the second and third dose. The meningococcal serogroup C serum bactericidal antibody (SBA) geometric mean titre (GMT) rose significantly from post-first dose (491, 95% CI 275, 877) to post-second dose (1052, 95% CI 774, 1433) (p = 0.03), with no significant change after the third dose (1024, 95% CI 768, 1366). An SBA titre of ≥8 was achieved by 92% after the first dose and 100% after the second and third doses. The Hib IgG geometric mean concentration (GMC) rose significantly after each dose: post-first (0.14 μg/ml 95% CI 0.10, 0.18), post-second (0.54 μg/ml, 95% CI 0.33, 0.90), post-third (2.04 μg/ml, 95% CI 1.52, 2.74). The Hib GMC after the third dose was higher than reported previously when this DTaP/Hib was given either on its own or concomitantly with a MCC-CRM conjugate vaccine according to the UK 2, 3 and 4 month schedule. This suggests some enhancement of the response to a Hib-TT vaccine by concomitant administration of MCC-TT. These results suggest that a reduced number of doses of MCC-TT would be adequate in infancy if given concomitantly with an acellular pertussis-containing vaccine.

AB - Reduction of the number of injections necessary to confer protection in the infant schedule would reduce discomfort, improve cost-effectiveness and create space for the addition of new vaccinations in the future. This study assessed the immunogenicity of one, two or three doses of meningococcal C conjugate vaccine conjugated to tetanus toxoid (MCC-TT) [Neis-VacC®] given concomitantly with a combined diphtheria/tetanus/acellular pertussis/Haemophilus influenzae type b -TT conjugate (DTaP-Hib-TT) [Infanrix-Hib®] vaccine at 2, 3 and 4 months of age. A total of 106 healthy UK infants were enrolled and randomised into two groups, one in which blood was taken after the first and third dose and the other after the second and third dose. The meningococcal serogroup C serum bactericidal antibody (SBA) geometric mean titre (GMT) rose significantly from post-first dose (491, 95% CI 275, 877) to post-second dose (1052, 95% CI 774, 1433) (p = 0.03), with no significant change after the third dose (1024, 95% CI 768, 1366). An SBA titre of ≥8 was achieved by 92% after the first dose and 100% after the second and third doses. The Hib IgG geometric mean concentration (GMC) rose significantly after each dose: post-first (0.14 μg/ml 95% CI 0.10, 0.18), post-second (0.54 μg/ml, 95% CI 0.33, 0.90), post-third (2.04 μg/ml, 95% CI 1.52, 2.74). The Hib GMC after the third dose was higher than reported previously when this DTaP/Hib was given either on its own or concomitantly with a MCC-CRM conjugate vaccine according to the UK 2, 3 and 4 month schedule. This suggests some enhancement of the response to a Hib-TT vaccine by concomitant administration of MCC-TT. These results suggest that a reduced number of doses of MCC-TT would be adequate in infancy if given concomitantly with an acellular pertussis-containing vaccine.

KW - Infant

KW - Meningococcal

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=28644448593&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.07.060

DO - 10.1016/j.vaccine.2005.07.060

M3 - Article

C2 - 16112255

AN - SCOPUS:28644448593

SN - 0264-410X

VL - 24

SP - 215

EP - 219

JO - Vaccine

JF - Vaccine

IS - 2

ER -

Southern J, Crowley-Luke A, Borrow R , Andrews N, Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine. 2006 Jan 12;24(2):215-219. doi: 10.1016/j.vaccine.2005.07.060

Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this